Skip to content
Oxford Vacmedix
  • Home
  • About
    • What We Do
    • Partnering Outlook
    • Management Team
    • Development Team
  • Technology
    • Technology
    • Recombinant Overlapping Peptide
    • T Cell Receptor
  • Pipeline
  • News
  • Contact

Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Publications / 2nd April 2020

Fenstermaker et al – 2016 (view as PDF)

Post navigation
← Previous Post
Next Post →

About Us

Our aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang – Recombinant Overlapping Peptides (ROP).

FIND OUT MORE

Useful Links

  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy

Main menu

  • Home
  • About
  • Technology
  • News
  • Contact
Copyright © 2023 Oxford Vacmedix | Website development by FDM Digital